arbiter
JournalsAccount

Lessons for the United States from Pharmaceutical Regulation Abroad

Margaret Kyle

Journal of Economic Perspectives2025https://doi.org/10.1257/jep.20241418article
AJG 4ABDC A*
Weight
0.48

Abstract

Pharmaceutical markets are characterized by barriers to entry and information problems. Many countries intervene in the pricing and reimbursement of drugs to a greater extent than the US government to date. Continued pressure from politicians and recent legislation are likely to change the market for pharmaceuticals in the United States. This article discusses the approaches adopted in other developed countries and the implications of their use in the United States, which due to its size, has far greater influence over the rate and direction of innovation. Alternative policy choices and the challenges of their implementation are also reviewed.

5 citations

Open via your library →

Cite this paper

https://doi.org/https://doi.org/10.1257/jep.20241418

Or copy a formatted citation

@article{margaret2025,
  title        = {{Lessons for the United States from Pharmaceutical Regulation Abroad}},
  author       = {Margaret Kyle},
  journal      = {Journal of Economic Perspectives},
  year         = {2025},
  doi          = {https://doi.org/https://doi.org/10.1257/jep.20241418},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Lessons for the United States from Pharmaceutical Regulation Abroad

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.48

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.41 × 0.4 = 0.16
M · momentum0.63 × 0.15 = 0.09
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.